Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension



Rating:

Share or cite this content

Citations should be made in the following way:
M. Orozco-Levi, L. Molina, V. Peinado, A. Ramirez-Sarmiento, V. Curull, L. Pijuan, B. Casado, F. Miranda, B. Vaquerizo, A. Serra, J. Gea, J. A. Barbera (Barcelona, Spain). Signs of MICA as an innate immune molecule potentially involved in vascular remodelling in patients with pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 1091

Member's Comments

No comment yet.

Related content which might interest you: Autoimmunity and pulmonary hypertension: a perspective Source: Eur Respir J 2005; 26: 1110-1118 Year: 2005 Pulmonary and systemic cellular immune response network in patients with mild-moderate COPD Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Soluble ADAM33 augments the pulmonary innate immune response promoting susceptibility to allergic airway inflammation Source: International Congress 2018 – Translational models of the immunopathology that underlies airway obstructive diseases Year: 2018 Treg alterations lead to systemic and local immune deregulation in idiopathic pulmonary fibrosis and collagen vascular disease-associated interstitial pneumonia Source: Annual Congress 2007 - Cell biology of asthma and COPD Year: 2007 Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Pulmonary defence mechanisms and inflammatory pathways in bronchiectasis Source: Eur Respir Mon 2011; 52: 11-21 Year: 2011 The Role of Inflammation in promoting pulmonary hypertension in idiopatchi and connective tissue disease-associated PAH Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension Year: 2008 Assessment of innate immunity mediators in the lung of COPD patients: relation with disease manifestations Source: Virtual Congress 2020 – Host-microbe interactions and their influence on lung disease onset and severity Year: 2020 Evaluation of specific immune complexes in patients with pulmonary sarcoidosis. Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management Year: 2018 Endothelial NO and its pathophysiologic regulation Source: Annual Congress 2007 - Role of the endothelium in pulmonary function and disease Year: 2007 Polymorphisms of innate immune response genes and severe systemic inflammatory response syndromes Source: Eur Respir J 2006; 28: Suppl. 50, 347s Year: 2006 The innate immune function of airway epithelial cells in inflammatory lung disease Source: Eur Respir J 2015; 45: 1150-1162 Year: 2015 Neurokinins contribute to vascular remodelling in a model of chronic pulmonary allergic inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 760s Year: 2006 The role of pathological angiogenesis in the pathogenesis of the chronic inflammatory lung diseases Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Relevance of innate immune responses to chronic airway diseases Source: Annual Congress 2008 - The battle between environmental “invaders” and airway epithelial defences Year: 2008 Microbes mediated host innate immune response in idiopathic pulmonary fibrosis Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 HIV-associated pulmonary arterial hypertension onset is associated with the soluble CD14 level and inflammation related to monocyte activation by LPS translocation from the gut Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Is soluble MICA facilitating tumor immune evasion in patients with COPD? Source: Annual Congress 2008 - Basic science in asthma and COPD II Year: 2008 COPD is associated with reduced pulmonary interstitial expression of pentraxin-3 Source: Eur Respir J 2012; 39: 830-838 Year: 2012 Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with BMPR2 mutation Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013